1,720,982 research outputs found
Serum opsonic activity in patients affected by gra-negative infections treated with azthreonam
No full text
Preincubation of Candida albicans strains with amphotericin B reduces tumor necrosis factor alpha and interleukin-6 release by human monocytes
No full textThe release of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL- 6) by human monocytes stimulated with whole heat-killed Candida albicans CA3 (a clinical isolate) and CA2 (a germ tube-negative mutant) either treated or not treated with amphotericin B was investigated. The optimal release of the cytokines was observed at 24 h of incubation of the yeasts with the monocytes for both TNF-α and IL-6. The levels ranged from 10,500 to 19,000 U/ml for TNF-α and from 350 to 460 pg/ml for IL-6. Germ tube-negative mutant CA2 induced the release of TNF-α at levels significantly (P < 0.05) lower than those induced by clinical isolate CA3, while no major differences were observed between the two strains with regard to their capacity to induce the release of IL-6. In all instances, preincubation of the yeasts with a sublethal concentration of amphotericin significantly reduced cytokine production. These results suggest that drug-induced alterations of fungal outer structures may affect the interactions between the yeasts and the monocytes, resulting in a reduced level of secretion of cytokines
Attività citotossica monocitaria indotta da gamma Interferon: studio a livello delle singole cellule.
No full textCinetica della produzione di TNF in un gruppo di pazienti ad alto rischio di sviluppare ARDS.
No full textREACTIVITY AND PROTECTIVE CAPACITY OF A POLYCLONAL ANTISERUM DERIVED FROM MICE IMMUNIZED WITH ANTIBIOTIC EXPOSED ESCHERICHIA-COLI
No full textThe murine immune response to Escherichia coli O6:K- alone or pre-exposed to 0.1 x MIC of aztreonam was investigated. Relative to mice immunized with untreated bacteria, mice immunized with antibiotic-treated microorganisms presented a significantly enhanced protection towards a challenge of 100 x LD50 of viable E. coli O6:K-. Previous injection of 0.1 mL of serum drawn from mice immunized with treated and untreated bacteria protected non-immunized mice towards a challenge of 10 x LD50 of viable E. coli O6:K-. Serum from mice immunized with treated bacteria also protected non-immunized mice towards a lethal challenge of E. coli O111. The antiserum contained high titre of IgG antibodies that cross-reacted with lipopolysaccharide isolated from smooth and rough Gram-negative bacteria. Immunoblotting showed additional bands of reactivity to the untreated E. coli O6:K-. Immunization with antibiotic-treated bacteria led to the production of type specific and cross reactive antibodies that protected animals against viable homologous and heterologous lethal challenges
Immunizzazione di topi con E. coli trattato con dosi sub-MIC di antibiotico monobattamico
No full text- …
